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The manner in which humans smoke cigarettes is an important determinant of smoking risks. Of the few
investigators that have predicted cancer risks from smoking on a chemical-specific basis, most used
mainstream cigarette smoke (MCS) carcinogen emissions obtained via machine smoking protocols that
only approximate human smoking conditions. Here we use data of Djordjevic et al. [Djordjevic, M.V.,
Stellman, S.D., Zang, E., 2000. Doses of nicotine and lung carcinogens delivered to cigarette smokers.
J. Natl. Cancer Inst. 92, 106–111] for MCS emissions of three carcinogens measured under human smok-
ing conditions to compute probability distributions of incremental lifetime cancer risk (ILCR) values using
Monte Carlo simulations. The three carcinogens considered are benzo[a]pyrene, N0-nitrosonornicotine
(NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Computed NNK ILCR values were
compared with lifetime risks of lung cancer (ILCRobsRlungCMD ) derived from American Cancer Society Cancer
Prevention Studies (CPS) I and II. Within the Monte Carlo simulation results, NNK was responsible for the
greatest ILCR values for all cancer endpoints: median ILCR values for NNK were 18-fold and 120-fold
higher than medians for NNN and benzo[a]pyrene, respectively. For ‘‘regular” cigarettes, the NNK median
ILCR for lung cancer was lower than ILCRobsRlungCMD from CPS-I and II by >90-fold for men and >4-fold for
women. Given what is known about chemical carcinogens in MCS, this study shows that there is a higher
incidence of lung cancer from exposure to MCS than can be predicted with current risk assessment meth-
ods using available toxicity and emission data.
 2009 Elsevier Inc. All rights reserved.1. Introduction
As early as the 1950s, smoking was recognized as a risk factor
for lung cancer (Doll and Hill, 1950, 1954, 1956; Wynder and
Graham, 1950; Hammond and Horn, 1958a,b), and later became
associated with many other respiratory and cardiovascular
diseases (US Department of Health and Human Services, 1964).
Nevertheless, though smoking prevalence in adults has decreased
significantly in the United States since the first US Surgeon General
Report in 1964 (from 42% in 1965 to 21% in 2004) (Centers forll rights reserved.
ronmental and Biomolecular
t Campus, 20000 NW Walker
48 1464.
nabe).Disease Control and Prevention, 2005), it is not decreasing at a rate
that will meet the goal of 12% set in Healthy People 2010 (US
Department of Health and Human Services, 2000). Unfortunately,
it is difficult to quit smoking (Hughes et al., 2004) and various
types of new tobacco products have been introduced in the last
decades with explicit and/or implied promises of greater relative
safety (Stratton et al., 2001), e.g., ‘‘light” and ‘‘ultralight” cigarettes
as well as newer ‘‘potentially reduced exposure product” (PREP)
cigarettes such as the EclipseTM. Epidemiologic determination of
the health risks of a given type of cigarette may only be possible
after smokers have been exposed to the product for at least
20 years. For example, approximately 30 years after the introduc-
tion of ‘‘light” cigarettes in the 1970s, recent reports (National
Cancer Institute, 2001; Harris et al., 2004) have described the fail-
ure of ‘‘light” (6 6 Federal Trade Commission (FTC) tar content
Nomenclature
Term Meaning (Units)
Ai Chemical i emission per cigarette (ng/cig)
ACS American Cancer Society
ANOVA analysis of variance
AT averaging time (days)
BaP benzo[a]pyrene
BW body weight (kg)
Cd cadmium
CDF cumulative distribution function
CDiz average (chronic) rate of daily intake of carcinogen i
from smoking when the total smoking dose is z pack-
years and, in this work, when the dose is averaged over
75 years (mg/kg-day)
CF conversion factor (106 mg/ng)
CIRCMD cumulative lung cancer incidence rate per 100,000 PYO
CMD cumulative mortality for all exposure durations
CMRCMD cumulative lung cancer mortality rate per 100,000
CPS-I6y Cancer Prevention Study I, six-year follow-up (1960 to
1966)
CPS-I12y Cancer Prevention Study I, 12-year follow-up (1960 to
1972)
CPS-II6y Cancer Prevention Study II six-year follow-up (1982 to
1988)
CSFi cancer slope factor for carcinogen i (also known as the
‘‘cancer potency” of i) (mg/kg-day)1
ED exposure duration (years)
EF exposure frequency (days/year)
FTC Federal Trade Commission
i a carcinogen of interest: BaP, NNN, or NNK
IARC International Agency for Research on Cancer
ILCRiz incremental lifetime cancer risk for carcinogen i for a
smoking dose of z pack-years (risk for z pack-years)
ILCRiz Average of ILCR
i
z values (risk for z pack-years)
ILCRiMCz Average of Monte Carlo simulated ILCR
i
z values
ILCRobsRlungCMD The incremental lifetime risk of being diagnosed
with lung cancer derived from epidemiologic data
ILCRNNKlungz incremental lifetime cancer risk for lung cancer
from exposure to NNK
LRCMD lifetime risk of being diagnosed with lung cancer
MC Monte Carlo
MCS mainstream cigarette smoke
NHANES National Health and Nutrition Examination Survey
NNK 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
NNN N0-nitrosonornicotine
PREP potentially reduced exposure product
PYO person-years of observation
q Pearson’s correlation coefficient
RIAGENDR NHANES subject gender
RIDAGEYR NHANES subject age (years)
SEER Surveillance, Epidemiology and End Results
SMD030 NHANES subject age at onset of smoking (years)
SMD070 NHANES subject average number of cigarettes smoked
per day (cig/day)
SMQ040 NHANES—whether or not the subject now smokes
SR average number of cigarettes smoked per day (aka
smoking rate or smoking intensity) (cig/day)
z smoking dose or total number of cigarettes smoked
(pack-years)
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duce smoking-related disease. Therefore, more expeditious meth-
ods of evaluating risks from currently marketed and PREP
cigarette products are needed, and one possible approach is to
compute risks on a toxicant-specific basis.
A few studies (Vorhees and Dodson, 1999; Fowles and Dybing,
2003; Pankow et al., 2007) implement methods to assess toxi-
cant-specific risks of mainstream cigarette smoke (MCS) from dif-
ferent brands and types of cigarettes. Vorhees and Dodson (1999)
first applied regulatory risk assessment methodology (US Environ-
mental Protection Agency, 2005) to compute incremental (excess)
lifetime cancer risks (ILCR) and non-cancer hazard quotients for 71
chemicals measured in MCS of 25 different cigarette brands,
although not all chemicals were measured in all cigarette brands.
They found 19 carcinogens (e.g., carcinogenic polycyclic aromatic
hydrocarbons, nitrosamines, and hydrazine) with chemical-spe-
cific cancer risks greater than 106 for a smoking dose of 30
pack-years (=20 cigarettes (one pack) per day for 30 years). An ILCR
value of 106 is the probability that 1 person may develop cancer
out of 1,000,000 people exposed to a carcinogen (US Environmen-
tal Protection Agency, 1991), and it is a commonly referenced
benchmark for the protection of public health (US Environmental
Protection Agency, 2004a,b). Fowles and Dybing (2003) assembled
data on 158 chemical constituents (including 41 carcinogens) in
MCS from published sources and developed a toxicological risk pri-
oritization index. They concluded that toxicological risk assess-
ment methods provide a sound basis for prioritizing chemical
toxicants in MCS, but also noted that estimates of actual cancer
risks are complicated by differences in toxicant emissions from cig-
arettes obtained by machine smoking protocols vs. emissions that
result under typical human smoking conditions. Pankow et al.
(2007) utilized available emission data obtained with machinesmoking protocols to assess carcinogen-specific ILCR values for
13 chemical carcinogens measured in MCS from 26 brands of con-
ventional cigarettes categorized as ‘‘regular”, ‘‘light”, and ‘‘ultra-
light”, and from eight brands of PREP cigarettes. Cancer risks
were calculated for an assumed smoking dose of one pack-year
(=7300 cigarettes), a body weight of 70 kg, and a 70-year lifetime.
Cumulative risks of exposure to the 13 carcinogens were computed
for each brand following an additive model (US Environmental Pro-
tection Agency, 1986; Krewski and Thomas, 1992). For all catego-
ries of cigarettes, at one pack-year, some carcinogen-specific
risks and cumulative risks exceeded 106 (Pankow et al., 2007) .
The three prior toxicant-specific risk investigations (Vorhees
and Dodson, 1999; Fowles and Dybing, 2003; Pankow et al.,
2007) used MCS chemical emissions measured by machine smok-
ing protocols, assumed constant values for parameters such as
smoking rate and body weight, and followed a deterministic ap-
proach for calculating risks. It is known, however, that a wide vari-
ety of smoking habits and histories will be found in any given
population of smokers, and that there are gender differences in
smoking habits and body weight distributions (National Center
for Health Statistics, 2005b; Melikian et al., 2007). As an extension
of these earlier studies, we performed a probabilistic analysis of
risks that accounts for uncertainty and variability in the way
people smoke cigarettes. Such an analysis requires population
distributions of MCS carcinogen emissions, smoking habits and
histories.
Of 69 known carcinogens in MCS (International Agency for
Research on Cancer, 2004), Djordjevic et al. (2000) measured BaP,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and N0-
nitrosonornicotine (NNN, unpublished) under human smoking
conditions. Though the data reported by Djordjevic et al. for 133
subjects are a subset of a larger dataset for 257 subjects recently
K.H. Watanabe et al. / Regulatory Toxicology and Pharmacology 55 (2009) 123–133 125published by Melikian et al. (2007), we believe that the 133 sub-
jects are representative of the larger dataset for important param-
eters such as smoking rate, duration, and the type of cigarette
smoked. BaP is a polycyclic aromatic hydrocarbon (Stellman and
Guidotti, 2006) classified as a human carcinogen by the Interna-
tional Agency for Research on Cancer (IARC) (Straif et al., 2005)
based on animal studies. NNN and NNK are tobacco-specific nitros-
amines that are also classified as human carcinogens by IARC
(Cogliano et al., 2004) based on animal studies. Of the 13 carcino-
gen-specific ILCR values computed by Pankow et al. (2007) for
‘‘regular” cigarettes and one pack-year of smoking, BaP, NNN, and
NNK have ILCR values of 5  107 (11th highest), 2  106 (9th
highest), and 4  105 (2nd highest), respectively.
In this study, we use BaP, NNN, and NNK emissions measured
under human smoking conditions, years of smoking, and the num-
ber of cigarettes smoked per day from Djordjevic et al. (2000), smo-
ker body weight data from the National Health and Nutrition
Examination Survey (NHANES) (2005b), and a Monte Carlo (MC)
method (US Environmental Protection Agency, 2001) to simulate
distributions of ILCR values. Other MCS carcinogens were not con-
sidered in this study because emission measurements under hu-
man smoking conditions were unavailable for individual smokers
and a sample size comparable to that of Djordjevic et al. To quan-
titatively evaluate how well carcinogen-specific ILCR values pre-
dict lung cancer risks derived epidemiologically, we compare
MC-simulated risks with lifetime lung cancer risks computed here
for the first time from two American Cancer Society epidemiolog-
ical studies, Cancer Prevention Studies (CPS) I and II.2. Methods
Pankow et al. (2007) used risk assessment methodology (US
Environmental Protection Agency, 2005) to determine incremental
lifetime cancer risk (ILCRiz) values for chemical carcinogen, i, in





where CDIiz (mg/kg-day) is the chronic daily intake (i.e., average dai-
ly dose, or total intake from the number of years of smoking aver-
aged over an expected lifespan); and CSFi (mg/kg-day)1 is the
cancer slope factor (aka cancer potency (California Environmental
Protection Agency, 2001, 2004)). Slight modification of the equa-
tions in Pankow et al. gives
ILCRiz ¼
Ai  SR  EF ED CF
BW AT  CSF
i
¼ A
i  7300 z CF
BW 27;375  CSF
i; ð2Þ
where Ai is chemical emission per cigarette (ng/cig); SR is the aver-
age number of cigarettes smoked per day (cig/day); EF is exposure
frequency (=365 days/year in this study); ED is exposure duration
(years of smoking); CF is a conversion factor (106 mg/ng); BW is
body weight (kg); AT is an averaging time (days) following US
EPA (US Environmental Protection Agency, 1989); and CSFi (mg/
kg-day)1 is the cancer slope factor (aka cancer potency (California
Environmental Protection Agency, 2001, 2004)). We departed from
US EPA guidance of a 70-year median human lifespan for AT and in-
stead used 75 years (27,375 days) to be consistent with increasing
life expectancy in the US (National Center for Health Statistics,
2005a). Multiplication of SR, EF, ED divided by 7300 cigarettes per
pack-year yields ILCRiz as a function of z (pack-years). Eq. (2) is a lin-
ear model where an equivalent ILCRiz value will be predicted for val-
ues of z that may be obtained in multiple ways, i.e., z = 1 pack-year
can be achieved by smoking one cigarette per day for 20 years, or 20cigarettes (one pack) per day for 1 year. Furthermore, the same
ILCRiz value will be predicted for former smokers and current smok-
ers who smoke the same number of pack-years. In this study, Ai, SR,
ED, and BW were treated as random variables to compute distribu-
tions of ILCRiz values; CSF
i, EF, CF and AT were assumed to remain
constant.
2.1. Characterization of Djordjevic et al. (2000) data
Djordjevic et al. (2000) studied the smoking topography of 133
users of low-nicotine and medium-nicotine yield cigarettes to
determine MCS emissions of selected carcinogens and toxicants
under actual human smoking conditions. For each subject, re-
corded data included SR, ED, BW, brand of cigarette with informa-
tion about size, type of pack, whether mentholated or not, and FTC
tar yield for the cigarette. For all 133 subjects, smoking parameters
such as puff volume, puff duration, interval between puffs, butt
length, and the degree of filter ventilation hole blocking were
determined. Then, for a randomly selected subset of 72 subjects,
smoking parameters were programmed into a smoking machine
to produce MCS samples from each subject’s brand of cigarette.
The MCS samples were analyzed for emissions of nicotine, carbon
monoxide, tar, BaP, NNK, and NNN; NNN data were not published
in Djordjevic et al. (2000).
We categorized cigarettes based upon FTC tar yields (Kozlowski
et al., 2001) as: ‘‘regular”, P15 mg tar/cig; ‘‘light”, 6 mg tar/cig to
<15 mg tar/cig; or ‘‘ultralight”, 1 mg tar/cig to <6 mg tar/cig. Six
of the 133 subjects in Djordjevic et al. smoked ‘‘ultralight” ciga-
rettes, and toxicant emissions were measured using the smoking
topography of only one of those six subjects. Because of the limited
toxicant emission data for ‘‘ultralight” cigarettes, we did not con-
sider this cigarette type in our analysis.
Table 1 summarizes the data from Djordjevic et al. pertaining to
the three carcinogens of interest along with the CSFi values that
were used to compute ILCRiz for 71 (=72  1) subjects. Pearson’s
chi-squared and Yate’s corrected chi-squared (for small sample
sizes) tests were used to compare SR, ED, BW, and Ai in men and
women separately in order to determine parameter independence
which is important for the MC simulations (Bois et al., 1991; Spear
et al., 1991; Woodruff et al., 1992; Watanabe et al., 1994) discussed
below. All parameters were found to be independent of each other
except for ANNN and ANNK. However, a lack of independence among
Ai values does not affect the use of the MC method because the MC
simulations were run separately for each carcinogen. Lognormal
distributions were fitted to the measurements of ABaP, ANNN and
ANNK grouped by gender and the type of cigarette smoked (‘‘regu-
lar” or ‘‘light”) using Systat 11 (see Table 1).
An analysis of variance (ANOVA) was performed to determine
whether we could combine SR values for ‘‘regular” and ‘‘light” cig-
arettes and both genders. No significant differences were found be-
tween the means for male smokers of ‘‘regular” (n = 36), and ‘‘light”
(n = 24) cigarettes, and female smokers of ‘‘regular” (n = 32), and
‘‘light” (n = 35) cigarettes. Thus, 127 SR values (both genders and
two cigarette types) were combined, and Systat 11 was used to
fit a lognormal distribution to the data. Similarly for ED values,
an ANOVA was performed that resulted in no significant differ-
ences based on gender or the type of cigarette smoked. Thus, ED
values for male and female smokers of ‘‘regular” and ‘‘light” ciga-
rettes were combined and a normal distribution was found to fit
the data best (Table 1). The normal distribution was truncated at
zero and 50 years to be consistent with observations from Djordj-
evic et al. Continuous distributions were fit to the SR and ED data
because these variables are likely to have a continuous range of
values in a population of smokers, whereas when surveyed, smok-
ers report whole numbers of cigarettes smoked per day and years
of smoking.
Table 1
Summary statistics (l = mean; r = standard deviation) for toxicant emissions, smoking rates and exposure durations from Djordjevic et al. (2000), and parameter definitions and distributions used to compute ILCRiz through Monte Carlo
simulation. BaP = benzo[a]pyrene; NNK = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; and NNN = N0-nitrosonornicotine.
Parameter Definition ‘‘Regular” cigarettes ‘‘Light” cigarettes Reference
Male smokers Female smokers Male smokers Female smokers
CSFBaP BaP cancer slope factor (mg/kg-day)1 3.9 3.9 3.9 3.9 California Environmental Protection Agency (2004)
CSFNNN NNN cancer slope factor (mg/kg-day)1 1.4 1.4 1.4 1.4 California Environmental Protection Agency (2004)
CSFNNK NNK cancer slope factor (mg/kg-day)1 49 49 49 49 California Environmental Protection Agency (2001)
EF Exposure frequency (days/year) 365 365 365 365
CF Conversion factor (mg/ng) 106 106 106 106
AT Averaging time (days) 27,375a 27,375a 27,375a 27,375a
ABaP BaP emission (ng/cig) n = 23 n = 14 n = 15 n = 19 Djordjevic et al. (2000)
l (r) 25 (10) 20 (4.4) 20 (13) 21 (6.6) Djordjevic et al. (2000)
Median 23 19 16 18 Djordjevic et al. (2000)
Distributionb LN(3.1, 0.41) LN(3.0, 0.21) LN(2.8, 0.54) LN(3.0, 0.32) this study
ANNK NNK emission (ng/cig) n = 23 n = 14 n = 15 n = 19 Djordjevic et al. (2000)
l (r) 271 (139) 280 (83) 207 (97) 216 (92) Djordjevic et al. (2000)
Median 215 292 212 193 Djordjevic et al. (2000)
Distributionb LN(5.5, 0.42) LN(5.6, 0.31) LN(5.2, 0.55) LN(5.3, 0.42) this study
ANNN NNN emission (ng/cig) n = 23 n = 14 n = 15 n = 19 Djordjevic et al. (2000)
l (r) 468 (150) 488 (135) 340 (168) 359 (140) Djordjevic et al. (2000)
Median 452 446 283 335 Djordjevic et al. (2000)
Distributionb LN(6.1,0.32) LN(6.2,0.28) LN(5.7, 0.51) LN(5.8, 0.39) this study
SR Average smoking rate (cig/day) n = 36 n = 32 n = 24 n = 35 Djordjevic et al. (2000)
l (r) 19 (9.7) 17 (8.7) 19 (15) 16 (5.8) Djordjevic et al. (2000)
Median 17 16 15 15 Djordjevic et al. (2000)
Distributionb LN(2.7, 0.47) LN(2.7, 0.47) LN(2.7, 0.47) LN(2.7, 0.47) this study
ED Exposure duration (years) n = 36 n = 32 n = 24 n = 35 Djordjevic et al. (2000)
l (r) 21 (9.8) 19 (11) 21 (12) 19 (12) Djordjevic et al. (2000)
Median 20 19 20 19 Djordjevic et al. (2000)
Distributionb TN(20, 11, 0, 50) TN(20, 11, 0, 50) TN(20, 11, 0, 50) TN(20, 11, 0, 50) this study
BW Body weight (kg) n = 36 n = 32 n = 24 n = 35 Djordjevic et al. (2000)
l (r) 82 (13) 69 (15) 82 (18) 62 (11) Djordjevic et al. (2000)
Median 84 66 82 59 Djordjevic et al. (2000)
Distributionb LN(4.4, 0.23) LN(4.3, 0.25) LN(4.4, 0.23) LN(4.3, 0.25) National Center for Health Statistics (2005b)
a Averaging time 75 years  365 days/year.
b Probability distribution abbreviations: LN = lognormal (M, SD) where M = mean of log-transformed data, and SD = standard deviation of log-transformed data; TN = truncated normal (l, r, LB, UB) where LB and UB are the

















1 Each participant is considered to contribute one person-year of observation for
each year they are in the study and a half-year in the year that they die from lung
cancer.
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We obtained the following SAS export files containing
NHANES 2001–2002 data (National Center for Health Statistics,
2005b) from the Centers for Disease Control: (1) Demographic
Variables and Sample Weights (demo_b.xpt) for age and gender;
(2) Body Measurements (bmx_b.xpt) for body weights; (3) and
Smoking and Tobacco Use (smq_b.xpt) for smoking-related data.
Data were imported into a Microsoft Access database, and related
by respondent sequence number (SEQN in all tables). A query for
respondent age, gender, smoking status and body weight was
run, then the results were exported to Systat 11 where lognormal
distributions were fitted separately to BW of adult (age 18+ years)
men and women smokers (see Table 1).
The NHANES 2001–2002 study provided an independent set of
SR and ED values in ‘‘everyday” smokers (906 respondents) for
evaluating our MC-simulated distributions of z. The NHANES
Smoking and Tobacco Use table was queried for: (1) whether the
study participant ‘‘now smokes cigarettes” (SMQ040, 1 indicates
a current smoker); (2) the average number of cigarettes smoked
per day (SMD070); and (3) the age at onset of smoking
(SMD030). Participants’ ages at the time of the survey (RIDAGEYR)
and gender (RIAGENDR) were obtained from the NHANES demo-
graphics table (demo_b). Values of z were computed for ‘‘everyday”
smokers (SMQ040 = 1) according to
zðSMQ040 ¼ 1Þ ¼ SMD070 365 YRS SMOKING
7300
; ð3Þ
where, YRS_SMOKING was calculated as the difference between a
respondent’s age (RIDAGEYR) and their reported age at onset of
smoking (SMQ030). It should be noted that this sample of ‘‘every-
day” smokers may include smokers who also use other forms of
tobacco, however, we do not expect this to have a large impact on
our analysis. A Kruskal–Wallis test was used to test for differences
between median z values from the Monte Carlo simulations,
Djordjevic et al. and NHANES.
2.3. Monte Carlo simulations
Smokers in a population are exposed to varying doses of MCS
carcinogens because of variability in Ai values, individual smoking
habits and exposure history. To account for population variability
in MCS carcinogen CDIiz values, a probabilistic MC simulation
approach used elsewhere (Bois et al., 1991; Spear et al., 1991;
Woodruff et al., 1992; Watanabe et al., 1994) was applied here.
Rather than sampling z, SR and ED were sampled separately be-
cause other studies have treated SR and ED as independent vari-
ables, e.g., in the analysis of: lung cancer incidence rates from a
20-year prospective study of British doctors (Doll and Peto, 1978),
lung cancer mortality rates from CPS-II (Flanders et al., 2003), and
the probability of lung cancer from a case–control study (Thurston
et al., 2005). MCSim software (Bois and Maszle, 1997) was used to
obtain randomly sampled values of Ai, SR, ED, and BW from their
probability distributions and to compute ILCRiz values.
Each iteration of an MC simulation computed an ILCRiz value
from a combination of the randomly sampled input parameters
with the parameters that were held constant (e.g., AT). Thus, a total
of 12 distributions were obtained, one for each combination of car-
cinogen (i.e., BaP, NNN, or NNK), gender, and the type of cigarette
smoked (i.e., ‘‘regular” or ‘‘light”). To determine how many itera-
tions were needed to provide a reasonable characterization of each
ILCRiz distribution, we performed 1,000, 5,000, and 100,000 itera-
tions for male smokers of ‘‘regular” cigarettes exposed to NNK. A
comparison of boxplots of CDINNKz showed no appreciable differ-
ence in the median and 90% confidence interval of each distribu-
tion, although larger numbers of iterations provided more CDINNKzvalues in the tails of the distribution (i.e., below the 10th percentile
and above the 90th percentile). Thus, 1000 iterations were per-
formed for the remaining the MC simulations.
2.4. Lifetime risks from epidemiologic studies
To evaluate the MC-simulated ILCRiz values, we calculated
ILCRobsRlungCMD from CPS-I and II data as documented by Smoking
and Tobacco Control Monograph 8 (1997); CMD is the total num-
ber of observed deaths for all exposure durations in an attained
age group. For 12 years of follow-up from 1960 to 1972 for CPS-I
(CPS-I12y), the available data include: the number of observed
deaths; total person-years of observation (PYO)1; never-smoker
mortality rates; excess mortality rates; and relative risks, all as strat-
ified by: SR groups of 1 to 9, 10 to 19, 20, 21 to 39, and 40+ cig/day;
ED groups of 0–4 years, 5–9, . . . , and 75–79 years; and attained age
groups of 40–44, 45–50, . . . , and 80–84 years. For 6 years of follow-
up from CPS-I (CPS-I6y, 1960–1966) and CPS-II (CPS-II6y, 1982–
1988), the published data are: observed deaths; PYO; and mortality
rates for never-smokers stratified by attained age from 50 to 85+
years in 5-year groups, and for smokers stratified by: SR values of
20 or 40 cig/day; ED from 30 to 50+ years in 5-year groups; and at-
tained age from 50 to 85+ in 5-year groups.
For each SR range we computed lifetime risks of being diag-
nosed with lung cancer (LRCMD) following Wun et al. (1998).
LRCMD ¼ 1 expðCIRCMD=100;000Þ; ð4Þ
where CIRCMD is the cumulative lung cancer incidence rate per
100,000 PYO. To obtain values of CIRCMD, cumulative lung cancer
mortality rates (CMRCMD) were computed as the sum of 5-year at-
tained age group mortality rates (per 100,000 PYO) multiplied by
5 years per age group.
Similarly, for never-smokers, a lifetime risk, LR0, was calculated
following the procedure outlined above using mortality rates from
a logistic regression model reported for CPS-I12y and observed
never-smoker mortality rates for CPS-I6y and CPS-II6y. Finally, the
incremental lifetime cancer risk of being diagnosed with lung can-
cer (ILCRobsRlungCMD ) was computed following Eq. (5) (see Online Sup-
plement for details).
ILCRobsRlungCMD ¼ LRCMD  LR0: ð5Þ3. Results
Computed ILCRiz values are reported in Table 2 for the 71 smok-
ers of ‘‘regular” and ‘‘light” cigarettes for whom ABaP, ANNN, and
ANNK values were measured by Djordjevic et al. For a particular cig-
arette type, statistically significant differences exist between ILCRiz
values for BaP, NNN, and NNK (paired t-test, all Bonferroni cor-
rected p-values <0.001), which is largely dependent upon the CSFi
value for each carcinogen. However, for each carcinogen, the ILCRiz
values are not significantly different for ‘‘regular” vs. ‘‘light” ciga-
rettes, or by smoker gender (Online Supplement Fig. S1).
Distributions of ILCRiMCz values obtained by MC simulations
(Fig. 1) followed the trends observed in the ILCRiz values derived
from the Djordjevic et al. data. While small differences were found
in the simulated ILCRiMCz distributions based on gender or ciga-
rette type for a given carcinogen, large differences exist between
ILCRiMCz values for the three carcinogens (see Table 3 for summary
statistics): median ILCRNNKMCz >> median ILCR
NNNMC
z >> median
ILCRBaPMCz . The means and medians of the MC-simulated
Table 2
Summary statistics of incremental lifetime cancer risks computed for 71 Djordjevic et al. (2000) study subjects. Values reported per 100,000: mean (ILCRiz); standard deviation
(r); median; 2.5th percentile; and 97.5th percentile for benzo[a]pyrene (BaP), N0-nitrosonornicotine (NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
CSFi = cancer slope factor for carcinogen i.
‘‘Regular” cigarettes ‘‘Light” cigarettes
Toxicant Male smokers (n = 23) Female smokers (n = 14) Male smokers (n = 15) Female smokers (n = 19)
Benzo[a]pyrene (BaP); CSFBaP = 3.9 (mg/kg-day)1
ILCRBaPz (r) 0.74 (0.87) 0.69 (0.81) 0.66 (0.78) 0.56 (0.45)
MedianBaP 0.49 0.43 0.38 0.37
2.5th percentile 0.10 0.080 0.028 0.069
97.5th percentile 3.0 2.5 2.5 1.5
N0-nitrosonornicotine (NNN); CSFNNN = 1.4 (mg/kg-day)1
ILCRNNNz (r) 4.8 (4.4) 5.7 (6.7) 3.8 (4.1) 4.0 (5.0)
MedianNNN 2.6 3.1 2.5 2.4
2.5th percentile 0.75 0.71 0.22 0.49
97.5th percentile 15 21 13 17
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK); CSFNNK = 49 (mg/kg-day)1
ILCRNNKz (r) 108 (139) 106 (108) 79 (72) 86 (113)
MedianNNK 47 78 62 49
2.5th percentile 14 15 4.4 8.2
97.5th percentile 499 348 208 374
Fig. 1. Results of 1000 Monte Carlo simulated incremental lifetime cancer risks
(ILCRiMCz ) for benzo[a]pyrene (BaP), N
0-nitrosonornicotine (NNN), and 4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Constant values used in calcula-
tions: EF = 365 days; CF = 106 mg/ng; and AT = 27,375 days. Random variables (Ai,
SR, ED and BW) were sampled from the distributions described in Table 1. The mid-
line of the box represents the median, the box edges are the 25th and 75th
percentiles, the whiskers are the 10th and 90th percentiles, and the points are the
5th and 95th percentiles. ‘‘Reg” denotes ‘‘regular” cigarettes having FTC tar content
P15 mg tar/cig, and ‘‘Lt” denotes ‘‘light” cigarettes having an FTC tar content of 6 to
<15 mg tar/cig.
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ues calculated from Djordjevic et al. reported in Table 2. All female
median ILCRiMCz values are slightly greater than the corresponding
male median ILCRiMCz values. This result is reasonable given that
the Djordjevic et al. data for ‘‘regular” cigarettes result in median
ILCRNNNz and ILCR
NNK
z values that are higher for female smokers than
for male smokers (see Table 2). The fitted distributions for Ai and
BW (Table 1) show that most of the female Ai distributions have
slightly higher medians than their male counterparts (exceptions
include BaP from ‘‘regular” cigarettes and NNK from ‘‘light” ciga-
rettes), and BW distributions for females have lower medians; both
of these differences contribute to the higher ILCRiMCz values for
females.
In the following comparison of ILCRiz with ILCR
obsRlung
CMD we focus
on risks from NNK because median ILCRNNKMCz values were 18
and 120 greater than the median ILCRNNNMCz and ILCR
BaPMC
z val-
ues, respectively. However, since ILCRNNKMCz predicts a risk corre-
sponding to being diagnosed with any type of cancer from NNKexposure, we computed ILCRNNKlungz values (Table 4) for lung can-
cer risk alone by using CSFNNK-lung (=28 (mg/kg-day)1) instead of
CSFNNK (=49 (mg/kg-day)1). A more detailed discussion of NNK
CSF values is provided in a California Environmental Protection
Agency report (2001).
Stratified by SR ranges, Table 4 summarizes ILCRobsRlungCMD values
from CPS-I and II, and median ILCRNNKlungz values from our MC sim-
ulations (values are reported per 100,000). For males, ILCRobsRlungCMD
values from CPS-I(6y&12y), ranged from 0.02 (SR = 1–9 cig/day) to
0.13 (SR = 40+ cig/day), and CPS-II6y ILCRobsRlungCMD values of 0.10
and 0.14 were found for SR equal to 20 and 40 cig/day, respec-
tively. Risks for females were much lower: CPS-I(6y&12y) risks ran-
ged from 0.0009 (SR = 1–9 cig/day) to 0.05 (SR = 21 to 39 and
40+ cig/day); and CPS-II6y risks of 0.07 and 0.10 were found for
SR = 20 and 40 cig/day, respectively.
Fig. 2 plots ILCRobsRlungCMD versus mid-range z values, where the
mid-range z value is halfway between the lowest and highest z val-
ues calculated for each SR range and an ED range from 1 to 69 years
of smoking. The lowest z value was calculated using the lowest SR
of an SR range, and ED of 1 year for CPS-I12y since a reported value
of 0 would pertain to a non-smoker (lower bound ED = 30 years for
CPS-I6y and CPS-II6y). Assuming that no smoker started before age
five, the upper bound was calculated with the highest SR for an SR
range and an ED of 69 years (upper bound ED = 50 years for CPS-I6y
and CPS-II6y) because lifetime risks were computed for attained
ages up to 74 years. For example, for SR = 1–9 cig/day and
ED = 1–69 years of smoking, z ranges from 0.05 to 31 pack-years;
the mid-range z value = 15.6. In Fig. 2, the relationship between
log ILCR and log z appears linear for both ILCRobsRlungCMD and
ILCRNNKlungz . However, we did not statistically evaluate the rela-
tionship between log ILCRobsRlungCMD and log z because of uncertainty
in the z values as depicted by the error bars.
We found median ILCRNNKlungz values determined by MC simu-
lation to be one to two orders of magnitude lower than ILCRobsRlungCMD
values. For smokers of ‘‘regular” cigarettes, median ILCRNNKlungz val-
ues compared to ILCRobsRlungCMD values from CPS-I
(6y&12y) and CPS-II6y
were lower for men by factors of 70–200, and for women by factors
of 5–100 (Table 4). In women, the smaller differences between
ILCRNNKlungz and ILCR
obsRlung
CMD arise because of much lower
ILCRobsRlungCMD derived from CPS-I data. Compared to ILCR
obsRlung
CMD val-
ues from CPS-II6y alone, median ILCRNNKlungz values for men are
lower by factors of 200 (SR = 20 cig/day) and 100 (SR = 40+ cig/
day); and median ILCRNNKlungz values for women are lower by
factors of 100 (SR = 20 cig/day) and 60 (SR = 40+ cig/day). Since
Table 3
Summary statistics for incremental lifetime cancer risk (per 100,000) from 1,000 Monte Carlo simulations: mean (ILCRiMCz ); standard deviation (r); median (median
i-MC); 2.5th
percentile and 97.5th percentile of the distribution; and ratios of Monte Carlo simulated ILCRiMCz mean and median values to Djordjevic et al. (2000) mean and median values for
benzo[a]pyrene (BaP), N0-nitrosonornicotine (NNN), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). CSFi = cancer slope factor for carcinogen i.
‘‘Regular” cigarettes ‘‘Light” cigarettes
Toxicant Male smokers Female smokers Male smokers Female smokers
Benzo[a]pyrene (BaP); CSFBaP = 3.9 (mg/kg-day)1
ILCRBaPMCz (r) 0.54 (0.54) 0.53 (0.53) 0.42 (0.48) 0.53 (0.46)
MedianBaP-MC 0.38 0.43 0.28 0.41
2.5th percentile 0.040 0.042 0.029 0.052
97.5th percentile 1.8 1.6 1.6 1.7
ILCRBaPMCz =ILCR
BaP
z 0.7 0.8 0.6 1.0
MedianBaP-MC/MedianBaP 0.8 1.0 0.7 1.1
N0-nitrosonornicotine (NNN); CSFNNN = 1.4 (mg/kg-day)1
ILCRNNNMCz (r) 3.8 (3.4) 4.8 (4.2) 2.8 (2.8) 3.2 (3.1)
MedianNNN-M 3.0 3.7 2.0 2.3
2.5th percentile 0.23 0.45 0.18 0.27
97.5th percentile 12 16 10 12
ILCRNNNMCz =ILCR
NNN
z 0.8 0.8 0.7 0.8
MedianNNN-MC/MedianNNN 1.1 1.2 0.8 1.0
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK); CSFNNK = 49 (mg/kg-day)1
ILCRNNKMCz (r) 73 (71) 87 (80) 58 (60) 71 (70)
MedianNNK-MC 53 66 38 50
2.5th percentile 5.3 5.8 3.9 4.2
97.5th percentile 242 311 239 246
ILCRNNKMCz =ILCR
NNK
z 0.7 0.8 0.7 0.8
MedianNNK-MC/MedianNNK 1.1 0.8 0.6 1.0
Table 4
Stratified by smoking rate, incremental lifetime cancer risks per 100,000 (ILCRobsRlungCMD ) calculated from American Cancer Society (ACS) Cancer Prevention Study (CPS) I and II
(National Cancer Institute, 1997), and median ILCRNNKlungz values from Monte Carlo simulations per 100,000.
Average smoking rate (cig/day) 1–9 10–19 20 21–39 40+
ACS CPS-I ILCRobsRlungCMD
12-year follow-upa,b
White male 1800 5100 7900 12,000 13,000
White female 95 750 2700 4800 4800
6-year follow-upa,b
White male — — 6700 — 10,000
White female — — 1300 — 3300
ACS CPS-II ILCRobsRlungCMD ; 6-year follow-up
a,b
White male — — 10,000 — 14,000
White female — — 7000 — 9800
Monte Carlo simulation of incremental lifetime cancer risks for lung cancer from NNKc exposure (ILCRNNKlungz )
Male smokers of ‘‘regular” cigarettesd 15 30 48 55 140
Male smokers of ‘‘light” cigarettesd 12 23 24 38 76
Female smokers of ‘‘regular” cigarettesd 20 38 68 68 180
Female smokers of ‘‘light” cigarettesd 16 27 48 58 100
a Calculated using mortality data, and incidence to mortality ratios determined from SEER data 1973–2002 (SEER, 2006a,b): CPS-I males = 1.2 for 1973; CPS-I females = 1.4
for 1973; CPS-II males = 1.1 for 1988; and CPS-II females = 1.4 for 1988.
b 12-year follow-up lifetime risks based on attained ages 40–74; 6-year follow-up lifetime risks based on attained ages 50–74.
c NNK is 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; cancer slope factor = 28 (mg/kg-day)1 for lung cancer as an endpoint only (California Environmental Pro-
tection Agency, 2001).
d Cigarette type determined from Federal Trade Commission tar content: ‘‘regular” P15 mg tar/cig; and ‘‘light”, 6 mg tar/cig to <15 mg tar.
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the 1970s, median ILCRNNKlungz for male and female smokers of
‘‘light” cigarettes were compared with only ILCRobsRlungCMD from
CPS-II6y. In men, ILCRNNKlungz values were lower than ILCR
obsRlung
CMD
values by factors of 400 (SR = 20 cig/day) and 200 (SR = 40 cig/
day); and in women the values differed by factors of 150 (SR = 20
cig/day) and 100 (SR = 40 cig/day).
For all ILCRobsRlungCMD values computed from CPS-I and II, values
for men are higher than values for women in each SR range. The
disparity is much greater for CPS-I6y&12y where ILCRobsRlungCMD values
for men are two to 20 times greater than values for women; for
CPS-II6y, ILCRobsRlungCMD values for men are 1.5 times greater than
values for women (see Section 4).3.1. Distributions of z
Using a Kruskal–Wallis test, we found no statistically significant
differences (p-value = 0.3) in the median z values of the four MC-
simulated distributions of z used in calculating NNK risks, z values
derived from Djordjevic et al. and z values derived from NHANES
(Online Supplement Fig. S2). The Kruskal–Wallis test, however, will
not detect all differences between the distributions, e.g., differ-
ences in variance (see below). Median z values from the MC simu-
lations are approximately equal to the medians observed for
subjects in Djordjevic et al. and NHANES (ratios range from 0.9
to 1.2). The NHANES z values in Fig. S2 support the low z values
(below the 10th percentile) obtained through MC simulation, but
3
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variances of the MC-simulated z-value distributions are smaller
than the variances of z values from Djordjevic et al. and NHANES.
4. Discussion
The benefit of the MC method used here over deterministic ap-
proaches used in other studies (Vorhees and Dodson, 1999; Fowles
and Dybing, 2003; Pankow et al., 2007) is the ability to account for
variability in how people smoke cigarettes. By randomly sampling
distributions for Ai, BW, SR, and ED that represent values from real
smokers, we obtained distributions of ILCR values that characterize
carcinogen-specific risks in male or female smokers of ‘‘regular” or
‘‘light” cigarettes. Values of Ai under human smoking conditions
were limited to measurements made by Djordjevic et al. (2000) be-
cause other data sets of comparable breadth and quality were not
available. For example, in a recent study, Werley et al. (2008) mea-
sured emissions of 48 chemicals (including BaP, NNN, and NNK) in
MCS of Marlboro Light which was machine-smoked under one hu-
man smoking condition protocol. However, these data cannot be
used in our study directly because SR, ED, and BW were not re-
ported, and we are interested in evaluating a range of human
smoking conditions not just one. In contrast, NHANES provided a
much larger database of smokers for determining BW distributions
for the MC simulations, and for evaluating our simulated distribu-
tions of z values.
Medians of the MC-simulated z-value distributions were consis-
tent with Djordjevic et al. and NHANES, but the variances of the
MC-simulated z-value distributions were smaller. Further exami-
nation of the empirical cumulative distribution functions (CDFs)
for SR and ED reveals that CDFs of SR from the MC simulations,
Djordjevic et al. and NHANES are all similar. And, ED CDFs from
the MC simulations are similar to the ED CDF from Djordjevic
et al. However, the MC-simulated ED distributions have lower vari-
ances than the NHANES ED distribution due to truncation of the
normal distribution at an upper bound of 50 years of smoking
determined from the Djordjevic et al. data. In contrast, NHANES
data indicate an upper bound of 70 years, which is consistent with
the upper limit on ED used to calculate ILCRobsRlungCMD values from
CPS-I12y. Since, ILCRiz is directly proportional to z, the resulting vari-
ances of the ILCRiMCz distributions should be lower than the vari-
ances in epidemiologically derived ILCRobsRlungCMD . Increasing the
upper bound on the ED distribution would increase both the MC-
simulated median z and median ILCRNNKlungz values resulting in a
shift of all MC-simulated points upward and to the right in Fig. 2.
Even with this adjustment, though, median ILCRNNKlungz values
would remain approximately one to two orders of magnitude low-
er than ILCRobsRlungCMD .
For Marlboro Light cigarettes machine-smoked under one hu-
man smoking condition, Werley et al. (2008) report emissions of
BaP (10.1 ng/cig), NNN (146 ng/cig), and NNK (92.7 ng/cig). These
emission values are 0.43–0.63 times lower than the median emis-
sion values measured by Djordjevic et al. (2000) for male and fe-
male smokers of ‘‘light” cigarettes, and used approximately 2
fewer puffs per cigarette and interpuff intervals about twice asFig. 2. Stratified by smoking rate (SR) ranges, median incremental lifetime cancer
risks from Monte Carlo simulation versus mid-range z values. r = median
ILCRNNKlungz for smokers of ‘‘regular” cigarettes; error bars mark the lower and
upper bounds of the simulated values. ILCRobsRlungCMD computed from data for attained
age up to 74 years and the sum of observed deaths over all exposure durations from
0 to 69 years: s = Cancer Prevention Study (CPS) I, 12-year follow-up; h = CPS-I, 6-
year follow-up; and D = CPS-II, 6-year follow-up. Results for: A—men; and B—
women.
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parameters held constant (e.g., SR, ED), a decrease in Ai will result
in a proportional decrease in ILCRiz given the linear dependence of
ILCRiz upon A
i.
We found CPS-I12y ILCRobsRlungCMD values for males to range from
2- to 20-fold greater than the corresponding value for females;
the largest fold-differences correspond to the two lowest SR
ranges, namely 1–9 and 10–19 cig/day. In the two lowest SR ranges
there were more PYO for women than men, whereas in the three
higher SR ranges there were more PYO for men than women
(ILCRobsRlungCMD for men are 2- to 3-fold greater than women). The
gender difference in ILCRobsRlungCMD can be attributed to differences
in excess mortality rates from CPS-I12y, and possible causes of this
have been of considerable interest. In Chapter 3 of Smoking and To-
bacco Control Monograph 8 (National Cancer Institute, 1997),
Burns et al. state:
‘‘Part of the difference between white males and white females in
relative and excess mortality is attributable to differences in dura-
tion of smoking between males and females of the same age, par-
ticularly among the older age groups. Males began to smoke
cigarettes in large numbers in the early part of this century,
whereas females initiated smoking during the late 1930’s and
1940’s (see Chapter 3). Female smokers in CPS-I also smoked fewer
cigarettes per day than male smokers, contributing to their lower
age-specific rate ratios.”
It is also possible that the difference is due to a lower degree of
smoke inhalation by women in CPS-I (Garfinkel and Stellman,
1988). The lower lung cancer risks observed for women in CPS-I
compared to men are in contrast to more recent studies that indi-
cate somewhat higher lung cancer risks for American women com-
pared to men (Risch et al., 1993; Zang and Wynder, 1996; US
Department of Health and Human Services, 2001; Belani et al.,
2007), and comparable risks for men and women in both Germany
and Italy (Kreuzer et al., 2000).
A challenge for the evaluation of cancer risk assessment meth-
odology is obtaining human epidemiologic data, ideally a prospec-
tive study where exposures are tracked over the course of the
study. For smoking, CPS-I and II are the best publicly available epi-
demiologic studies that provide data to calculate ILCRobsRlungCMD val-
ues. However, a limitation of comparing CPS-I and II data with
ILCRiz values computed for chemical emissions from cigarettes is
the time frame over which these studies were conducted because
of changes in cigarette design. We categorized cigarettes as ‘‘regu-
lar” or ‘‘light” based on FTC tar content, however, cigarettes avail-
able at the time CPS-I and II were conducted (1960–1972 and
1982–1988, respectively) may have had higher FTC tar content.
Thus, MCS emissions may have contained different amounts of
BaP, NNN, and NNK since positive correlations have been shown
between BaP, NNN, and NNK emissions and FTC tar content
(Borgerding et al., 2000). Based upon the regression equations in
Borgerding et al., an increase in FTC tar content from 15 to
25 mg/cig would result in 40% more BaP, 17% more NNN, and
14% more NNK. These numbers suggest higher CPS-period cigarette
carcinogen emissions than those measured by Djordjevic et al.
(2000), which would result in a proportional increase in carcino-
gen-specific ILCR values, but it is inconclusive whether the increase
can account for the large differences between risks based on
chemical carcinogen emissions and the values derived from CPS-I
and II.
There has been discussion in the literature of how epidemiol-
ogic data have been used in various phases of quantitative risk
assessment (Shore et al., 1992; Hertz-Picciotto, 1995; Wartenberg
and Simon, 1995; Samet et al., 1998; Goldman, 2001), and a few
studies have compared risks based on human dose–response data
(primarily from occupational exposures) with risks computed fromanimal bioassay dose–response data (Allen et al., 1988; Hertz-Pic-
ciotto et al., 1988; Hertz-Picciotto and Hu, 1994). For 23 chemicals,
Allen et al. (1988) compared the daily doses (mg/kg-day) that
would cause cancer deaths in 25% of the exposed individuals de-
rived from human epidemiologic studies and animal bioassay stud-
ies. They concluded that animal bioassay data were reasonable for
quantifying human risks. For the risk of contact-site tumors from
ethylene dibromide, Hertz-Picciotto et al. (1988) found excess risks
computed from animal bioassay data to be consistent with human
data. However, Hertz-Picciotto and Hu (1994) found that smoking-
induced lung cancer risk attributable to cadmium (Cd) in MCS ran-
ged from 13% to 18% of lung cancer risks derived from two differ-
ent epidemiologic studies (Kahn, 1966; Mattson et al., 1987), but
concluded that this overestimated the risks of Cd in MCS given
the large number of known carcinogens in MCS.
The present study differs from previous work (Allen et al., 1988;
Hertz-Picciotto et al., 1988; Hertz-Picciotto and Hu, 1994) in that
CSFi values derived from animal bioassay data were used to com-
pute ILCR values for a range of human exposure scenarios and
MCS carcinogen emissions measured under human smoking condi-
tions, then the ILCR values were compared to lifetime risks derived
from CPS-I and II. The best available CSFi values were used, but it
should be noted that for NNK, CSFNNK values (e.g., for lung cancer
or all cancer endpoints) were derived from animals exposed to
NNK in drinking water rather than by inhalation (California Envi-
ronmental Protection Agency, 2001). This study shows that median
ILCRNNKlungz values for male smokers of ‘‘regular” or ‘‘light” ciga-
rettes explain only 0.2–1% of the lung cancer risk in men derived
from CPS-I and II; for female smokers median ILCRNNKlungz values
explain 0.7–21% of the risks derived from CPS-I and II. For females,
if CPS-I ILCRobsRlungCMD values are excluded because the female values
are much lower than the male values, median ILCRNNKlungz values
explain 0.7–2% of the epidemiologically derived risk. Accounting
for higher carcinogen emissions in CPS-period cigarettes and inclu-
sion of other MCS carcinogens to compute a cumulative risk fol-
lowing an additive risk model (US Environmental Protection
Agency, 1986; Krewski and Thomas, 1992) as done by Pankow
et al. (2007) would reduce the difference between risks based on
chemical carcinogen emissions and the values derived from CPS-I
and II. However, results from this study indicate that for men, this
would require the equivalent of 100 lung carcinogens having the
same magnitude of risk as NNK out of the 69 known MCS carcino-
gens. Moreover, an examination of ILCR values calculated for 13
carcinogens by Pankow et al. (2007) and 30 carcinogens by Vorh-
ees and Dodson (1999) (all cancer endpoints included), yields at
most nine carcinogens (i.e., in alphabetical order, 1,3-butadiene,
acetaldehyde, acrylonitrile, arsenic, benzene, cadmium, formalde-
hyde, NNN and quinoline) with risk values of the same order of
magnitude or within one order of magnitude below the NNK risk
(see Pankow et al. (2007) Supplementary Fig. S1). These findings
suggest that MCS may cause a much higher incidence of lung can-
cer than can be predicted from current risk assessment methods on
a carcinogen-specific basis with available toxicity data and emis-
sion data measured under human smoking conditions. This conclu-
sion stems from the fact that any given sample of cigarette smoke
is a complex chemical mixture that contains not only complete car-
cinogens such as NNK, NNN, and BaP, but also many chemicals that
are co-carcinogens, cancer initiators, or cancer promoters (Loeb
et al., 1984; Preston-Martin et al., 1991; Hoffmann and Hoffmann,
2001; Lemjabbar et al., 2003; Hazelton et al., 2005). It is therefore
quite possible that complete removal of NNK, NNN, and BaP from
mainstream smoke of PREP products would bring little or no
reduction in cancer risks due to smoking, which is consistent with
the views of Loeb et al. (1984) and Pankow et al. (2007). Further-
more, whether an individual develops lung cancer depends
upon individual susceptibility due to genetic, behavioral and
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of these effects are subject to amplification when yet other chem-
icals impair normal lung clearing functions so that carcinogens and
toxicants can reside in the respiratory tract for relatively longer
periods of time. Thus, for the protection of public health, it is more
important to reduce smoking than to create cigarette products that
attempt to reduce risks from smoking by removing selected chem-
icals from tobacco smoke.
The assessment of cancer risk from exposure to complex chem-
ical mixtures such as MCS, requires a risk assessment approach
that accounts for risk contributions from chemicals that are not
complete carcinogens such as initiators and promoters, or combi-
nations of such chemicals. Biologically based, multistage cancer
models (Ellwein and Cohen, 1992; Moolgavkar and Luebeck,
1995) can simulate tumor probabilities from exposure to complete
carcinogens, and combinations of initiators and promoters, but as a
predictive tool such models require more data (e.g., the probabili-
ties that cells will undergo mutations, cell proliferation, birth and
death rates as functions of the carcinogen(s) of interest, etc.) than
the ILCR approach used here. Thus, additional studies are needed to
measure MCS chemical emissions, and to assess the toxicity and
mechanisms of action of MCS chemicals. Furthermore, as with
other complex chemical mixtures to which humans are exposed,
more research is needed to develop better risk assessment meth-
ods and models that account for the biological complexities of
smoking-induced cancers.Acknowledgments
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